Description: GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.
Home Page: www.ghres.com
GHRS Technical Analysis
28 Baggot Street Lower
Dublin,
D02 NX43
Ireland
Phone:
353 1 437 8443
Officers
| Name | Title |
|---|---|
| Mr. Florian Schonharting M.Sc. (Econ) | Co-Founder & Non-Exec. Chairman |
| Mr. Theis Terwey M.D. | Co-Founder & CEO |
| Mr. Magnus Halle | Co-Founder & MD of Ireland |
| Ms. Julie Ryan A.C.A. | VP of Fin. |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.1985 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-06-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 14 |